$202.5 million in state support has been identified across nine states to replace federal Medicaid money blocked for Planned Parenthood and similar providers, with New York's still-undisclosed reimbursements excluded from that total.
The funding response followed Section 71113 of the 2025 budget law, enacted July 4, 2025, which imposed a one-year ban on Medicaid reimbursements to certain reproductive health entities that provide abortion services.
California accounts for the largest share with more than $140 million, while Oregon allocated $17.5 million, Washington $11 million and Connecticut $10.4 million; Illinois, Massachusetts, Maine and Colorado added smaller sums.
New Jersey and New Mexico also opened $11 million for reproductive health providers likely to include Planned Parenthood, underscoring how states are using one-time appropriations and state-only reimbursement mechanisms to offset the federal cutoff.
Most of the measures are tied to current budget cycles and could lapse at fiscal year-end, leaving the durability of these state backfills uncertain.
The federal ban just ended. What happens now to the emergency state funds propping up reproductive health clinics?
States spent over $200 million to fill a funding gap. Did this intervention actually prevent a collapse in patient care?
The Fallout of the 2025 Federal Medicaid Ban: Access, Funding, and the Ongoing Political Battle Over Reproductive Healthcare
Overview
On July 1, 2026, the federal Medicaid ban expired, but this did not lead to greater access to abortion services for Medicaid enrollees. This is because a long-standing rider on government spending bills still blocks federal funds from being used for abortions, except in limited cases. At the same time, a new law signed by President Donald Trump in 2025 introduced fresh restrictions, removing federal Medicaid funding from organizations that provide abortions and received significant reimbursements. As a result, major reproductive health providers like Planned Parenthood continue to face financial challenges, and the overall funding landscape remains complex and restrictive.